DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.
This drug has thirty-eight patent family members in fourteen countries.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
A generic version of RYTARY was approved as carbidopa; levodopa by MAYNE PHARMA on August 28th, 1992.
Summary for RYTARY
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||4|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for RYTARY|
|Drug Sales Revenues:||Drug sales revenues for RYTARY|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for RYTARY|
|What excipients (inactive ingredients) are in RYTARY?||RYTARY excipients list|
|DailyMed Link:||RYTARY at DailyMed|
|Country||Patent Number||Estimated Expiration|
|Australia||2008343787||⤷ Free Forever Trial|
|Japan||2011507956||⤷ Free Forever Trial|
|European Patent Office||1507518||⤷ Free Forever Trial|
|Taiwan||200633730||⤷ Free Forever Trial|
|China||101910113||⤷ Free Forever Trial|
|South Korea||20100099731||⤷ Free Forever Trial|
|World Intellectual Property Organization (WIPO)||03101432||⤷ Free Forever Trial|
|>Country||>Patent Number||>Estimated Expiration|